<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289807</url>
  </required_header>
  <id_info>
    <org_study_id>SYSYCC-2014-11</org_study_id>
    <nct_id>NCT02289807</nct_id>
  </id_info>
  <brief_title>Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy</brief_title>
  <official_title>Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard
      treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National
      Comprehensive Cancer Network guideline. However these recommendations were based on the
      evidence in the two-dimensional conventional radiotherapy (2DCRT) era. The introduction of
      intensity-modulated radiotherapy (IMRT) in NPC treatment has brought substantial better
      treatment outcomes than 2DCRT. It has been questioned whether additional concurrent
      chemotherapy is still necessary for intermediate risk NPC within the excellent framework of
      IMRT. hus, we jointly conduct the first non-inferior randomized trial to determine the value
      of concurrent chemotherapy with cisplatin for intermediate risk NPC patients treated with
      IMRT. Given the results of clinical studies mentioned above, we decide to adopt the
      concurrent regimen to be cisplatin 100 mg/m2 on day 1, 22, 43
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients Patients with non-keratinizing NPC T1-2N1M0/T2-3N0M0 (UICC/AJCC 7th edition) are
      randomly assigned to receive CCRT or RT alone. Patients in CCRT group receive cisplatin 100
      mg/m² every 3 weeks for 3 cycles, concurrently with intensity-modulated radiotherapy (IMRT).
      IMRT is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to
      a total dose of 66 Gy or greater to the primary tumor. Our primary endpoint is failure-free
      survival(FFS). Secondary end points include overall survival (OS), locoregional failure-free
      survival (LR-FFS), distant failure-free survival (D-FFS) rates and toxic effects. All
      efficacy analyses are conducted in the intention-to-treat population, and the safety
      population include only patients who receive their randomly assigned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>3 Year</time_frame>
    <description>Failure-free survival rate is calculated from the date of randomization to the date of treatment failure or death from any cause, whichever is first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 Year</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival</measure>
    <time_frame>3 Year</time_frame>
    <description>Locoregional failure-free survival is calculated from randomization to the first locoregional failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant failure-free survival</measure>
    <time_frame>3 Year</time_frame>
    <description>Distant failure-free survival is calculated from randomization to the first remote failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>3 Year</time_frame>
    <description>Incidence of acute and late toxicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intensity modulated-radiotherapy (IMRT) alone Patients receive intensity modulated-radiotherapy (IMRT) alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCRT group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT and concurrent cisplatin Patients receive intensity modulated-radiotherapy (IMRT), concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT</description>
    <arm_group_label>CCRT group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor</description>
    <arm_group_label>RT group</arm_group_label>
    <arm_group_label>CCRT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with newly histologically confirmed non-keratinizing (according to WHO
        histologically type).

        Tumor staged as T1-2N1/T2-3N0(according to the 7th AJCC edition). No evidence of distant
        metastasis (M0). Satisfactory performance status: Karnofsky scale (KPS) ≥ 70. Adequate
        marrow: leucocyte count ≥ 4000/μL, hemoglobin ≥ 90g/L and platelet count ≥ 100000/μL.

        Normal liver function test: Alanine Aminotransferase (ALT), Aspartate Aminotransferase
        (AST) &lt; 1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP) ≤
        2.5×ULN, and bilirubin ≤ ULN.

        Adequate renal function: creatinine clearance ≥ 60 ml/min. Patients must be informed of the
        investigational nature of this study and give written informed consent.

        Exclusion Criteria:

        WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.

        Age &gt; 65 or &lt; 18. Treatment with palliative intent. Prior malignancy except adequately
        treated basal cell or squamous cell skin cancer, in situ cervical cancer.

        Pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize
        effective contraception during the treatment period).

        History of previous RT (except for non-melanomatous skin cancers outside intended RT
        treatment volume).

        Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. Any severe
        intercurrent disease, which may bring unacceptable risk or affect the compliance of the
        trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic
        hepatitis, diabetes with poor control (fasting plasma glucose &gt; 1.5×ULN), and emotional
        disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Ma, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Ma, M.D.</last_name>
    <phone>+86-20-87343469</phone>
    <email>majun2@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Chua DT, Sham JS, Kwong DL, Au GK. Treatment outcome after radiotherapy alone for patients with Stage I-II nasopharyngeal carcinoma. Cancer. 2003 Jul 1;98(1):74-80.</citation>
    <PMID>12833458</PMID>
  </reference>
  <reference>
    <citation>Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1070-6. doi: 10.1016/j.ijrobp.2008.09.008. Epub 2009 Feb 21.</citation>
    <PMID>19231110</PMID>
  </reference>
  <reference>
    <citation>Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011 Dec 7;103(23):1761-70. doi: 10.1093/jnci/djr432. Epub 2011 Nov 4.</citation>
    <PMID>22056739</PMID>
  </reference>
  <reference>
    <citation>Song CH, Wu HG, Heo DS, Kim KH, Sung MW, Park CI. Treatment outcomes for radiotherapy alone are comparable with neoadjuvant chemotherapy followed by radiotherapy in early-stage nasopharyngeal carcinoma. Laryngoscope. 2008 Apr;118(4):663-70. doi: 10.1097/MLG.0b013e3181626cfe.</citation>
    <PMID>18216741</PMID>
  </reference>
  <reference>
    <citation>Chua DT, Ma J, Sham JS, Mai HQ, Choy DT, Hong MH, Lu TX, Au GK, Min HQ. Improvement of survival after addition of induction chemotherapy to radiotherapy in patients with early-stage nasopharyngeal carcinoma: Subgroup analysis of two Phase III trials. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1300-6. Epub 2006 Jun 5.</citation>
    <PMID>16750333</PMID>
  </reference>
  <reference>
    <citation>Xu T, Hu C, Wang X, Shen C. Role of chemoradiotherapy in intermediate prognosis nasopharyngeal carcinoma. Oral Oncol. 2011 May;47(5):408-13. doi: 10.1016/j.oraloncology.2011.03.008. Epub 2011 Apr 2.</citation>
    <PMID>21459659</PMID>
  </reference>
  <reference>
    <citation>Lai SZ, Li WF, Chen L, Luo W, Chen YY, Liu LZ, Sun Y, Lin AH, Liu MZ, Ma J. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):661-8. doi: 10.1016/j.ijrobp.2010.03.024. Epub 2010 Jul 17.</citation>
    <PMID>20643517</PMID>
  </reference>
  <reference>
    <citation>Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012 Sep;104(3):286-93. doi: 10.1016/j.radonc.2012.08.013. Epub 2012 Sep 17.</citation>
    <PMID>22995588</PMID>
  </reference>
  <reference>
    <citation>Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, Chan OS, Chang AT, Yeung RM. Evolution of treatment for nasopharyngeal cancer--success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014 Mar;110(3):377-84. doi: 10.1016/j.radonc.2014.02.003. Epub 2014 Mar 11. Review.</citation>
    <PMID>24630534</PMID>
  </reference>
  <reference>
    <citation>Su SF, Han F, Zhao C, Chen CY, Xiao WW, Li JX, Lu TX. Long-term outcomes of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy alone. Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):327-33. doi: 10.1016/j.ijrobp.2010.09.011. Epub 2010 Oct 29.</citation>
    <PMID>21035959</PMID>
  </reference>
  <reference>
    <citation>Tham IW, Lin S, Pan J, Han L, Lu JJ, Wee J. Intensity-modulated radiation therapy without concurrent chemotherapy for stage IIb nasopharyngeal cancer. Am J Clin Oncol. 2010 Jun;33(3):294-9. doi: 10.1097/COC.0b013e3181d2edab.</citation>
    <PMID>20395788</PMID>
  </reference>
  <reference>
    <citation>Luo S, Zhao L, Wang J, Xu M, Li J, Zhou B, Xiao F, Long X, Shi M. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck. 2014 Jun;36(6):841-7. doi: 10.1002/hed.23386. Epub 2013 Oct 4.</citation>
    <PMID>23720240</PMID>
  </reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>November 10, 2014</last_update_submitted>
  <last_update_submitted_qc>November 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jun Ma,MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Concurrent chemoradiotherapy</keyword>
  <keyword>intermediate risk</keyword>
  <keyword>intensity-modulated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

